

# The role of neurophysiology in the differential diagnosis of amyotrophic lateral sclerosis

**Markus Weber**

Neuromuscular Diseases Unit/ALS Clinic, Kantonsspital  
St.Gallen

# New methods

Grolez et al. *BMC Neurology* (2016) 16:155  
DOI 10.1186/s12883-016-0672-6

BMC Neurology

RESEARCH ARTICLE

Open Access



## The value of magnetic resonance imaging as a biomarker for amyotrophic lateral sclerosis: a systematic review

G. Grolez<sup>1,2</sup>, C. Moreau<sup>1,2</sup>, V. Danel-Brunaud<sup>1,2</sup>, C. Delmaire<sup>2,3</sup>, R. Lopes<sup>2,3</sup>, P. F. Pradat<sup>4,5</sup>, M. M. El Mendili<sup>4</sup>, I. Dafeburra<sup>1,2</sup> and D. Devos<sup>1,2,6\*</sup>

Comparative Study > *Radiology*. 2019 Jul;292(1):149-156. doi: 10.1148/radiol.2019182538.

Epub 2019 May 7.

## Amyotrophic Lateral Sclerosis versus Multifocal Motor Neuropathy: Utility of MR Neurography

Moritz Kronlage<sup>1</sup>, Karl Christian Knop<sup>1</sup>, Daniel Schwarz<sup>1</sup>, Tim Godel<sup>1</sup>, Sabine Heiland<sup>1</sup>, Martin Bendszus<sup>1</sup>, Philipp Bäumer<sup>1</sup>

> *Clin Neurophysiol*. 2017 Jun;128(6):1069-1074. doi: 10.1016/j.clinph.2017.02.015. Epub 2017 Mar 1.

## A muscle ultrasound score in the diagnosis of amyotrophic lateral sclerosis

Yukiko Tsuji<sup>1</sup>, Yu-Ichi Noto<sup>2</sup>, Kensuke Shiga<sup>3</sup>, Satoshi Teramukai<sup>4</sup>, Masanori Nakagawa<sup>5</sup>,

Clinical Trial > *J Neurol*. 2015;262(4):870-80. doi: 10.1007/s00415-015-7648-0. Epub 2015 Jan 28.

## Nerve ultrasound for differentiation between amyotrophic lateral sclerosis and multifocal motor neuropathy

Alexander Grimm<sup>1</sup>, Bernhard F Décard, Ioanna Athanasopoulou, Kathi Schweikert, Michael Sinnreich, Hubertus Axer


ARTICLE CLASS OF EVIDENCE

## Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis

Emily Feneberg, MD, Patrick Oeckl, PhD, Petra Steinacker, PhD, Federico Verde, MD, Christian Barro, Philip Van Damme, MD, PhD, Elizabeth Gray, PhD, Julian Grosskreutz, MD, Claude Jardel, PharmD, PhD, Jens Kuhle, MD, PhD, Sonja Koerner, MD, Foudil Lamari, MD, PhD, Maria del Mar Amador, MD, Benjamin Mayer, PhD, Claudia Morelli, MD, Petra Muckova, PhD, Susanne Petri, MD, Koen Poesen, PharmD, PhD, Joost Raaphorst, MD, François Salachas, MD, Vincenzo Silani, MD, Beatrice Stubendorff, PhD, Martin R. Turner, PhD, Marcel M. Verbeek, PhD, MSc, Jochen H. Weishaupt, MD, Patrick Weydt, MD, Albert C. Ludolph, MD, and Markus Otto, MD

**Correspondence**  
Dr. Otto  
markus.otto@uni-ulm.de

## Andrew Eisen:



The clinical context of the Edx exam is of **essential** importance


**ALS is never diagnosed on  
Edx criteria alone**

## Differentialdiagnosis: simplification

- Pure motor syndrome (usually focal in onset)
  - Weakness
  - Wasting
- Progression over months-years
- «plus symptoms»
  - Cramps
  - fasciculations

# Diagnostic delay in ALS : ISIS survey

(Chio, J Neurol. 1999, ALS 2000)



- 201 patients (USA, Argentina, Brazil Germany, Spain, Italy)
- Onset – diagnosis: 14 months (12-17)

- Time taken by neurologist to confirm diagnosis
- First symptom to first consultation with a neurologist
- First symptom to first consultation

# Diagnostic delay in ALS : ISIS survey

(Chio, J Neurol. 1999, ALS 2000)

- Misdiagnosis (45%)
  - Neuropathy
  - Medullary compression
  - Periarthritis
  - Cerebral stroke
  - Narrow spinal canal
  - Osteoporosis
- Neurologists 28%, GPs 29%, orthopedic surgeons 26%, other specialists 18%

J Neurol Sci. 2014 Aug 15;343(1-2):173-5. doi: 10.1016/j.jns.2014.06.003. Epub 2014 Jun 12.

## **Delayed diagnosis in ALS: the problem continues.**

Nzwalo H<sup>1</sup>, de Abreu D<sup>2</sup>, Swash M<sup>3</sup>, Pinto S<sup>4</sup>, de Carvalho M<sup>5</sup>.

- Median time 9.5 months

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep;15(5-6):453-6. doi: 10.3109/21678421.2014.903974. Epub 2014 Jul 1.


## **Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS).**

Paganoni S<sup>1</sup>, Macklin EA, Lee A, Murphy A, Chang J, Zipf A, Cudkowicz M, Atassi N.

- Median time 11.5 months
- In average 3 different physicians before diagnosis
- 52% received an alternative diagnosis
  - Neuropathy (28%)
  - Spine disease (18%)

# *El Escorial criteria 1994*

*(Brooks et al. J. Neurol.Sci. 1994)*





# Real Sitio de San Lorenzo de El Escorial



Built 1563 -1584 by King [Philipp II.](#) of [Spain](#)  
Largest [Renaissance building worldwide](#)


# Diagnostic investigations: ISIS survey

(Chio, ALS 2000)


- EMG: 90%
  - Requested by neurologist in 90%
  - Requested by other specialists 10%
- MRI (cervical and lumbar): 66%
- CSF: 30%
- Muscle biopsy: 20%

# Shortening the time post-onset

(Brooks. J Neurol Sci 1999)



# Revised El Escorial criteria (Brooks et al. ALS 2000)



# *Electrophysiological Features of LMN Dysfunction* (revised El Escorial criteria 2000)

- **Conventional EMG studies**  
**The features of LMN dysfunction ...are defined by electromyographic ....evidence of**
  - **active *and***
  - **chronic denervation**
  - **fasciculations.**

## EMG findings (EEC, 2000)

- Active denervation:
  - spontaneous activity (fibrillation potentials, positive sharp waves)
- Chronic denervation:
  - impaired MUP recruitment (rapid firing)
  - unstable MUPs (Jiggle)
  - abnormal MUP size and shape (polyphasic potentials)

# Jiggle (unstable motor unit potential) ALS





Clinical Neurophysiology 119 (2008) 497–503



[www.elsevier.com/locate/clinph](http://www.elsevier.com/locate/clinph)

## Review

# Electrodiagnostic criteria for diagnosis of ALS <sup>☆</sup>

Mamede de Carvalho <sup>a</sup>, Reinhard Dengler <sup>b</sup>, Andrew Eisen <sup>c</sup>, John D. England <sup>d</sup>,  
Ryuji Kaji <sup>e</sup>, Jun Kimura <sup>f</sup>, Kerry Mills <sup>g</sup>, Hiroshi Mitsumoto <sup>h</sup>,  
Hiroyuki Nodera <sup>i</sup>, Jeremy Shefner <sup>j</sup>, Michael Swash <sup>k,\*</sup>

<sup>a</sup> Department of Neurology, Hospital de Santa Maria, University of Lisbon, Lisbon, Portugal

<sup>b</sup> Department of Neurology, Medizinische Hochschule Hannover, Germany

<sup>c</sup> Department of Neurology, University of British Columbia, Vancouver, Canada

<sup>d</sup> Department of Neurology, Billings Clinic, Billings, MT, USA

<sup>e</sup> Department of Neurology, Tokushima University Graduate School of Medicine, Tokushima-city, Japan

<sup>f</sup> Department of Neurology, University of Iowa, Iowa City, USA

<sup>g</sup> Department of Neurology, Kings College Hospital, Guys Kings and St. Thomas's School of Medicine, London, UK

<sup>h</sup> Eleanor and Lou Gehrig ALS Center, Neurological Institute, Columbia University, NY, USA

<sup>i</sup> Department of Neurology, Tokushima University, Tokushima-city, Japan

<sup>j</sup> Department of Neurology, Upstate Medical University, Syracuse, NY, USA

<sup>k</sup> Department of Neurology, Royal London Hospital, Queen Mary University of London, London, UK




# Awaji consensus

1. *Edx and clinical data* are of equal and interchangeable value in diagnosing ALS
2. *In the presence of signs of partial denervation*, Fasciculation potentials (preferably of complex morphology) are equivalent to fibs-psw, indicating ongoing denervation
3. *Fibs and psws* are usually recorded in **strong, non-wasted** muscles
4. *Unstable MUPs & FPs* are especially relevant

# Do clinicians apply the EE category correctly?

N=399 patients with suspected ALS



**Diagnostic criteria for amyotrophic lateral sclerosis: A multicentre study of inter-rater variation and sensitivity.** Johnsen et al..Clin Neurophysiol. 2019 Feb

# Revisions: possible ALS = ALS

Editorial

> Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5-6):291-2.

doi: 10.3109/21678421.2015.1049183. Epub 2015 Jun 29.

## A revision of the El Escorial criteria – 2015

Albert Ludolph<sup>1</sup>, Vivian Drory<sup>2</sup>, Orla Hardiman<sup>3</sup>, Imaharu Nakano<sup>4</sup>, John Ravits<sup>5</sup>,  
Wim Robberecht<sup>6</sup>, Jeremy Shefner<sup>7</sup>, WFN Research Group On ALS/MND

Clinical Neurophysiology 131 (2020) 1975–1978



ELSEVIER

Contents lists available at [ScienceDirect](#)

Clinical Neurophysiology

journal homepage: [www.elsevier.com/locate/clinph](http://www.elsevier.com/locate/clinph)



Opinion Paper

A proposal for new diagnostic criteria for ALS

Jeremy M. Shefner<sup>a,\*</sup>, Ammar Al-Chalabi<sup>b</sup>, Mark R. Baker<sup>c</sup>, Li-Ying Cui<sup>d</sup>,



# Possible ALS = ALS


Clinical Neurophysiology 131 (2020) 1975–1978



Contents lists available at [ScienceDirect](#)

Clinical Neurophysiology

journal homepage: [www.elsevier.com/locate/clinph](http://www.elsevier.com/locate/clinph)



Opinion Paper

A proposal for new diagnostic criteria for ALS


Jeremy M. Shefner<sup>a,\*</sup>, Ammar Al-Chalabi<sup>b</sup>, Mark R. Baker<sup>c</sup>, Li-Ying Cui<sup>d</sup>,



EMG abnormalities that must include:  
Both evidence of chronic neurogenic change, defined by **large motor unit potentials** of increased duration and/or **increased amplitude**, with polyphasia and motor unit instability regarded as supportive but not obligatory evidence


RESEARCH PAPER

## Fasciculation potentials and earliest changes in motor unit physiology in ALS

Mamede de Carvalho,<sup>1,2</sup> Michael Swash<sup>1,2,3</sup>Carvalho M, et al. *J Neurol Neurosurg Psychiatry* 2013;84:963–968

**Figure 2** Progression of 13 amyotrophic lateral sclerosis patients with isolated fasciculation potentials (FPs) (normal motor unit potential (MUP) and no fibrillation/sharp-waves (fibs-sw)). All patients were evaluate 6 months later, but only four had preserved normal tibialis anterior strength 12 months after study entry. The Y-axis represents the number of patients.

**Andrew Eisen:**  
**The clinical context of the Edx exam is**  
**essential importance**





**ALS is never diagnosed on**  
**Edx criteria alone**

**“Pattern recognition”**



Video with permission of  
the patient

Letters to the editor  
Flail arm  
syndrome: a  
distinctive variant  
of amyotrophic  
lateral sclerosis  
T M HU,  
C M ELLIS,  
A AL-CHALABI,  
P N LEIGH,  
C E SHAW





# Clues for differential diagnosis of pure motor syndromes

## ALS

- Clinical:
  - split hand, foot drop etc
  - Finger flexors usually strong
  - Grade of weakness and wasting are proportional
  - Tongue wasting and fasciculations: 80% predictive value for ALS
  - If no fasciculations: consider alternative diagnosis
- Neurophysiology
  - chronic EMG changes (EE)
  - Unstable MUPS, Jiggle (EE, Awaji)
  - Signs of active denervation in strong muscles (Awaji)
- One region (Gold coast) with upper and lower MN signs=ALS

# Clues for differential diagnosis of pure motor syndromes


## **MMN (*multifocal motor neuropathy*)**

- Clinical
  - Pattern of weakness can be attributed to specific nerves (e.g. radial, ulnar)
  - huge discrepancy between high-graded weakness and only modest atrophy of muscles (clinical sign of a “conduction block”)
  - especially recognizable in patients with short disease duration (a few months)
- Neurophysiology: Hunting for signs of demyelination (F-waves, conduction block)
  - Weak (mild atrophic) muscle with no spontaneous activity but complex, unstable MUPs
  - Recruitment pattern („rapid firing“) dysproportional to atrophy
  - Fasciculation potentials may be seen
  - NCS: high threshold for nerve stimulation

# Clues for differential diagnosis of pure motor syndromes


## **IBM (inclusion body myositis)**

- Clinical
  - weakness and atrophy of knee extensors and finger flexors
  - In ALS finger flexors are usually strong until advanced disease stages
- Neurophysiology
  - large complex potentials frequent, but components are „spiky“
  - „myopathic“ potentials sometimes hard to find
  - CRDs are more likely in myopathies
  - Look at thoracic paraspinals: if frank denervation and less than in limb muscles myopathy more likely
  - Hyperrecruitment
  - no rapid firing, no fasciculations, **no Jiggle**



# Clues for differential diagnosis of pure motor syndrome

## Kennedy disease



ARTICLE


OPEN ACCESS

*Neurology*<sup>®</sup> 2019;93:e895-e907. Klickovic et al.


## Skeletal muscle MRI differentiates SBMA and ALS and correlates with disease severity

- Clinical
  - Gynecomastia, quivering of the chin, **absent** ankle jerk, high CK (>2000U/l)
- Neurophysiology
  - large MUPs (> 8 mV, like in Polio), **no** sural SNAP

# EMG changes in ALS: Fasciculations



# Fasciculations



# Fasciculations







# Clues for differential diagnosis of pure motor syndromes

## Benign cramp/fasciculation and fasciculation anxiety syndrome

### ■ Clinical

- you will receive photos and videos before you see the patient
- «yes doctor I believe you, but.....»
- medical students and staff more likely to have fasciculation anxiety syndrome
- [Fasciculation anxiety syndrome in clinicians.](#) Simon NG, Kiernan MC.Simon NG, et al. J Neurol. 2013 Jul;260(7):1743-7. doi: 10.1007/s00415-013-6856-8. Epub 2013 Feb 12.
- [A prospective study of benign fasciculation syndrome and anxiety.](#) Filippakis A, Jara J, Ventura N, Scala S, Scopa C, Ruthazer R, Karakis I, Srinivasan J, Russell JA, Ho DT.Filippakis A, et al. Muscle Nerve. 2018 Dec;58(6):852-854. doi: 10.1002/mus.26193. Epub 2018 Sep 11.



### ■ Neurophysiology:

- EMG: Don't needle calf muscles
- (Rare) fasics may be found above the knee but **MUPs don't jiggle**

# Questions?



# History



# Differentialdiagnosis: EFNS guidelines 2012

**Table 17.3** Diseases that can masquerade as ALS/MND.

**Anatomical abnormalities/compression syndromes**

Arnold–Chiari type 1 and other hindbrain malformations  
Cervical, foramen magnum, or posterior fossa region tumours  
Cervical disc herniation with osteochondrosis  
Cervical meningioma  
Retropharyngeal tumour  
Spinal epidural cyst  
Spondylotic myelopathy and/or motor radiculopathy  
Syringomyelia

**Acquired enzyme defects**

Adult GM<sub>2</sub> gangliosidosis (hexosaminidase A or B deficiency)  
Polyglucosan body disease

**Autoimmune syndromes**

Monoclonal gammopathy with motor neuropathy  
Multifocal motor neuropathy with/without conduction block  
Dysimmune lower motor neuron syndromes (with GM<sub>1</sub>, GD<sub>1b</sub>, and asialo-GM<sub>2</sub> antibodies)  
Other dysimmune lower motor neuron syndromes, including chronic inflammatory demyelinating polyneuropathy  
Multiple sclerosis  
Myasthenia gravis (in particular the anti-muscle-specific receptor tyrosine kinase positive variant)

**Endocrine abnormalities**

Allgrove syndrome  
Diabetic ‘amyotrophy’  
Insulinoma causing neuropathy  
Hyperthyroidism with myopathy  
Hypothyroidism with myopathy  
Hyperparathyroidism (primary)  
Hyperparathyroidism (secondary due to vitamin D deficiency)  
Hypokalemia (Conn’s syndrome)

**Exogenous toxins**

Lead (?), mercury (?), cadmium, aluminium, arsenic, thallium, manganese, organic pesticides; neurolethyrism, konzo

**Infections**

Acute poliomyelitis  
Post-poliomyelitis progressive muscular atrophy syndrome  
HIV-1 (with vacuolar myelopathy)  
HTLV-1-associated myelopathy (tropical spastic paraplegia)  
Neuroborreliosis  
Syphilitic hypertrophic pachymeningitis  
Spinal encephalitis lethargica, varicella-zoster  
Trichinosis  
Brucellosis, cat-scratch disease  
Prion disorders

**Myopathies**

Cachectic myopathy  
Carcinoid myopathy  
Dystrophin-deficient myopathy  
Inclusion body myositis  
Inflammatory myopathies

Nemaline myopathy  
Polymyositis  
Sarcoid myositis

**Neoplastic syndromes**

Chronic lymphocytic leukemia  
Intramedullary glioma  
Lymphoproliferative disorders with paraproteinemia and/or oligoclonal bands in the cerebrospinal fluid  
Pancoast tumour syndrome  
Paraneoplastic encephalomyelitis with anterior horn cell involvement  
‘Stiff person plus’ syndromes

**Physical injury**

Electric shock neuropathy  
Radiation-induced radiculo-plexopathies and/myelopathy

**Vascular disorders**

Arteriovenous malformation  
Dejerine’s anterior bulbar artery syndrome  
Stroke  
Vasculitis

**Other neurological conditions**

Western Pacific atypical forms of MND/ALS (Guam, New Guinea, Kii Peninsula of Japan)  
Caribbean atypical forms of MND–dementia–PSP (Guadeloupe)  
Madras-form of juvenile onset MND/ALS (South India)  
Frontotemporal dementia with MND/ALS (including Pick’s disease with amyotrophy)  
Multiple system atrophy  
Olivo-ponto cerebellar atrophy syndromes  
Primary lateral sclerosis (some subtypes not related to ALS)  
Progressive encephalomyelitis with rigidity  
PSP  
Hereditary spastic paraplegia (many variants, some subtypes with distal amyotrophy)  
Progressive spinal muscular atrophy (some subtypes not related to ALS)  
Spinobulbar muscular atrophy with/without dynactin or androgen receptor mutation  
Spinal muscular atrophy I–IV  
Brown–Vialeto–van Laere syndrome (early-onset bulbar and spinal ALS with sensorineural deafness)  
Fazio–Londe syndrome (infantile progressive bulbar palsy)  
Harper–Young syndrome (laryngeal and distal spinal muscular atrophy)  
Monomelic sporadic spinal muscular atrophy (benign focal amyotrophy, including Hirayama syndrome)  
Polyneuropathies with dominating motor symptoms (like hereditary motor and sensory neuropathy type 2, hereditary motor neuropathy type 5)  
Familial amyloid polyneuropathy  
Benign fasciculations  
Myokymia

ALS, amyotrophic lateral sclerosis; MDN, motor neuron disease; PSP, Progressive supranuclear palsy.

# Lab recommendations: EFNS guidelines 2012

**Table 17.2** Diagnosing amyotrophic lateral sclerosis/motor neuron disease: recommended investigations.

Test	Evidence class	Recommended mandatory tests	Recommended additional tests in selected cases
<b>Clinical chemistry</b>			
<b>Blood</b>			
Erythrocyte sedimentation rate	IV	x	–
C-reactive protein	IV	x	–
Haematological screen	IV	x	–
Aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase	IV	x	–
Thyroid-stimulating hormone, free T <sub>4</sub> , free T <sub>3</sub> hormone assays	IV	x	–
Vitamin B <sub>12</sub> and folate	IV	x	–
Serum protein electrophoresis	IV	x	–
Serum immunoelectrophoresis	IV	x	–
Creatine kinase	IV	x	–
Creatinine	IV	x	–
Electrolytes (Na <sup>+</sup> , K <sup>+</sup> , Cl <sup>-</sup> , Ca <sup>2+</sup> , HPO <sub>4</sub> <sup>2-</sup> )	IV	x	–
Glucose	IV	x	–
Angiotensin-converting enzyme	IV	–	x
Lactate	IV	–	x
Hexoaminidase A and B assay	IV	–	x
Ganglioside GM-1 antibodies	IV	–	x
Anti-Hu, anti-MAG	IV	–	x
RA, antinuclear antibodies, anti-DNA	IV	–	x
Anti-acetylcholine receptor and anti-muscle-specific receptor tyrosine kinase antibodies	IV	–	x
Serology ( <i>Borrelia</i> , virus including HIV)	IV	–	x
DNA analysis (for details see Supplementary Figure 6.1 online)	IV	–	x
<b>CSF</b>			
Cell count	IV	–	x
Cytology	IV	–	x
Total protein concentration	IV	–	x
Glucose, lactate	IV	–	x
Protein electrophoresis including IgG index	IV	–	x
Serology ( <i>Borrelia</i> , virus)	IV	–	x
Ganglioside antibodies	IV	–	x

## ALS mimics

- **Misdiagnosis (false positive)**
  - Scottish Motor Neuron Disease Register, Davenport et al. 1996
    - 10% out of 552 incident cases
    - 1. Cervical spondylotic myelopathy
    - 2. MND plus syndromes
    - 3. MS
  - Ireland, population-based study, Traynor et al. 2000
    - 7.3 % out of 437 referrals
    - 1. MMN
    - 2. Kennedy disease
    - 3. Motor neuropathy
- **Missed diagnosis (false negative)**
  - Bulbar onset ALS, Turner et al. 2010
    - 50 % referred to another speciality prior to diagnosis (otolaryngology, stroke clinics)
  - Retrospective (neurological) cohorts (Srinivasan et al. 2006; Kraemer et al 2010)
    - 12 % surgery prior to diagnosis
  - Retrospective (neurosurgical) cohorts (Yoshor et al. 2005)
    - 4.2% out of 1131 spinal decompressive surgery

# Gold Coast diagnostic criteria: Implications for ALS diagnosis and clinical trial enrollment.

Steve Vucic et al. M&N, Nov 2021

**TABLE 1** Diagnostic criteria for ALS

	Revised El Escorial criteria (2000) <sup>5</sup>	Awaji criteria <sup>a</sup> (2008) <sup>6</sup>	Gold Coast criteria <sup>b</sup> (2019) <sup>7</sup>
Presence of ALS	Different diagnostic categories (see below)	Different diagnostic categories (see below)	Progressive motor impairment documented by history or repeated clinical assessment, preceded by normal motor function, <b>AND</b> Presence of UMN and LMN dysfunction in at least one body region, <b>OR</b> LMN dysfunction in at least two body regions, <b>AND</b> Investigations excluding other disease processes
Definite ALS	UMN and LMN signs in three spinal regions, <b>OR</b> Bulbar region and two spinal regions	UMN and LMN signs in three spinal regions, <b>OR</b> Bulbar region and two spinal regions	Abolished
Probable ALS	UMN and LMN signs in at least two regions with some UMN signs necessarily rostral to (above) the LMN signs	UMN and LMN signs in at least two regions with some UMN signs necessarily rostral to (above) the LMN signs	Abolished
Clinically probable ALS: laboratory-supported	UMN and LMN signs in one region, <b>OR</b> UMN signs alone present in one region, and LMN signs defined by EMG criteria present in at least two regions	Category abolished	
Possible ALS	UMN and LMN signs in one region, <b>OR</b> UMN signs in two or more regions; <b>OR</b> LMN signs are found rostral to UMN signs and the diagnosis of clinically probable ALS-laboratory-supported cannot be proven	UMN and LMN signs in one region, <b>OR</b> UMN signs in two or more regions; <b>OR</b> LMN signs are found rostral to UMN signs Neuroimaging and clinical laboratory studies will have been performed and other diagnoses must have been excluded	Abolished